Profil
Dr. Harry Kopelman, MD, is Scientific Advisor at Easton Capital Investment Group.
Dr. Kopelman is a graduate of the Georgetown University School of Medicine, Washington, D.C.
(1980).
He completed his internship/residency at North Carolina Memorial Hospital/University of North Carolina, Chapel Hill (1983).
His fellowship in Cardiovascular Disease and Cardiac Electrophysiology was at the Vanderbilt University School of Medicine in Nashville, TN (1985).
Ehemalige bekannte Positionen von Harry Kopelman
| Unternehmen | Position | Ende |
|---|---|---|
Arterain Medical, Inc.
Arterain Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices to treat large vessel acute ischemic strokes | Direktor/Vorstandsmitglied | - |
Easton Capital Investment Group
Easton Capital Investment Group Investment ManagersFinance Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor. | Corporate Officer/Principal | - |
Ausbildung von Harry Kopelman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Arterain Medical, Inc.
Arterain Medical, Inc. Medical SpecialtiesHealth Technology Develops medical devices to treat large vessel acute ischemic strokes | Health Technology |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Easton Capital Investment Group
Easton Capital Investment Group Investment ManagersFinance Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor. | Finance |
















